All

Prophylactic Group

p*

Subgroup

p*

Amiodarone

Placebo

POAF

NO POAF

Characteristics

N (%)

228 (100)

114 (50)

114 (50)

N/A

47 (21)

181 (79)

N/A

Age (mean, SD)

66 (59; 72)

65 (59; 71)

66 (59; 74)

0.405

68 (62; 74)

64 (58; 71)

0.081

Sex (male, n (%))

117 (51)

57 (50)

60 (52)

0.691

27 (57)

90 (50)

0.345

Current smoker (n (%))

86 (38)

39 (34)

47 (41)

0.274

17 (36)

69 (38)

0.806

Diabetes mellitus (n (%))

21 (9)

14 (12)

7 (6)

0.109

4 (9)

17 (9)

1.000

Hypertension (n (%))

75 (33)

43 (38)

32 (28)

0.121

22 (47)

53 (29)

0.023*

Hypercholesterolemia (n (%))

34 (15)

19 (17)

15 (13)

0.457

8 (17)

26 (14)

0.649

COPD (n (%))

23 (10)

13 (11)

10 (9)

0.509

5 (11)

18 (10)

1.000

Previous MI (n (%))

4 (2)

**

**

1.000

**

**

1.000

Preoperative use of β-blockers (n (%))

29 (13)

16 (14)

13 (11)

0.551

7 (15)

22 (12)

0.616

Creatinine (μmol/L) (median, IQR)

66 (57; 77)

66 (58; 77)

65 (54; 76)

0.180

68 (60; 78)

65 (55; 76)

0.081

Peri- and Postoperative Characteristics

Postoperative atrial fibrillation (n (%))

47 (21)

10 (9)

37 (33)

<0.001*

47 (21)

181 (79)

N/A

Postoperative arrhythmia (n (%))

**

**

**

N/A

**

**

N/A

Postoperative blockage (n (%))

**

**

**

N/A

**

**

N/A

Reoperation (n (%))

8 (4)

5 (5)

**

0.499

**

6 (3)

0.668

Right side lobectomy (n (%))

120 (53)

59 (52)

61 (54)

0.791

26 (55)

94 (52)

0.679

Bilobectomy (n (%))

5 (2)

**

**

1.000

**

**

0.061

Pneumonectomy (n (%))

8 (4)

4 (4)

4 (4)

1.000

**

6 (3)

0.670

Tumour stage (n (%))

Tumour I

87 (39)

39 (35)

48 (43)

0.260

19 (40)

68 (38)

0.802

Tumour II

99 (44)

56 (51)

43 (38)

0.062

23 (49)

76 (43)

0.462

Tumour III

31 (14)

13 (12)

18 (16)

0.361

**

28 (16)

0.096

Tumour IV

7 (3)

**

4(4)

1.000

**

5 (3)

0.639

Nodulus stage (n (%))

Nodulus I

32 (14)

15 (14)

17 (15)

0.743

6 (13)

26 (15)

0.738

Nodulus II

36 (16)

14 (13)

22 (20)

0.162

7 (15)

29 (16)

0.805

Metastasis stage (n (%))

Metastasis I

10 (5)

5 (5)

5 (4)

1.000

**

9 (5)

0.692

Metastasis II

**

**

**

N/A

**

**

N/A

Tumour size (mm) (median, IQR)

31 (20; 50)

32 (20; 50)

30 (20; 45)

0.671

30 (20; 41)

32(20; 50)

0.669

Length of stay in ICU (days) (median, IQR)

1 (1; 1)

1 (1; 1)

1 (1; 1)

0.774

1 (1; 1)

1 (1; 1)

0.785

Length of stay in referring department (days) (median, IQR)

4 (3; 5)

4 (3; 5)

4 (3; 5)

0.699

4 (3; 5)

4 (3; 5)

0.334